Combined Therapeutics (CTx) is a privately held biotechnology company founded with the mission to develop next-generation mRNA vaccines and therapies. The company's vision is to protect vulnerable populations from global infectious diseases and treat cancer using their proprietary mRNA platform. This platform features increased safety through controlled biodistribution and high specificity, leveraging Multi Organ Protective (MOPCTx) binding miRNA sequences combined with therapeutic mRNAs.
CTx has attracted notable investors and experts in the biotech field, contributing to its rapid advancements in pre-clinical stages. The company’s key achievements include the development of a unique mRNA platform that promises higher safety and efficacy. By focusing on both infectious diseases and cancer, CTx aims to make a significant impact on global health, particularly for populations that are most at risk.
